Obesity Injections, Tirzepatide (Mounjaro) Posted on 01 July 2025

A pathway is being developed in our ICB area (North East and North Cumbria) for the delivery of weight loss injections. We currently do not have a contract for delivering this at Haltwhistle Medical Group. As soon as we are in a position to offer the treatment we will update this notice.

 To be eligible for the NHS injection a patient must have a BMI ≥40 and 4 out of the following 5 conditions.:

·         Atherosclerotic Cardiovascular Disease – IHD, CVA/TIA, PAD, HF

·         Hypertension – On treatment

·         High Cholesterol – On Lipid Lowering Therapy (or LDL >=4.1 or HDL <1.0 for men or HDL <1.3 women or fasting triglycerides >=1.7)

·         Obstructive Sleep Apnoea (OSA) – Meets criteria for CPAP or equivalent

·         Diabetes Type 2

Phased Primary Care Cohorts (2025–2028)

The programme will develop over the coming years as follows:

·         Cohort I (2025-26 ):  4 or more of the comorbidities listed above and BMI ≥40

·         Cohort II (2026-27):  4 or more comorbidities listed above and BMI 35-39.9

·         Cohort III (2026-2028):  3 or more comorbidities listed above and BMI ≥40